U.S., Aug. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07109869) titled 'Safety and Efficacy of Boric Acid Inserts for Treatment of Vulvovaginal Candidiasis' on July 31.
Brief Summary: This is a Phase 3 clinical study to evaluate the efficacy, safety, and tolerability of boric acid 600 mg vaginal inserts in patients with VVC.
Study Start Date: Aug., 2025
Study Type: INTERVENTIONAL
Condition:
Vulvovaginal Candidiases
Vulvovaginal Candidiasis, Genital
Vulvovaginal Candidiasis (VVC)
Intervention:
DRUG: Boric acid
Boric acid vaginal inserts consisting of 600 mg boric acid drug substance filled into white, opaque hypromellose capsules with no additional excipients included in the formulation. Each vagin...